CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Increase in the number of cancer and diabetic patients
4.1.2. Growth in the biologics market
4.1.3. Technological advancements and new product launches
4.1.4. Increase in demand for self-injection devices
4.1.5. Growing competition in emerging economies and high demand for injectable drug
delivery
4.2. Market Restraints & Challenges
4.2.1. Infections associated with needlestick injuries
4.2.2. Availability of other drug delivery methods
4.2.3. Product recalls
4.3. Market Opportunities
4.3.1. Rising demand for biosimilars and generic injectables
CHAPTER 5 GLOBAL INJECTABLE DRUG DELIVERY MARKET – BY TYPE
5.1. Devices
5.1.1. Conventional Injection Devices
5.1.2. Self-Injection Devices
5.1.2.1. Needle-Free Injectors
5.1.2.2. Auto-Injectors
5.1.2.3. Pen Injectors
5.1.2.4. Wearable Injectors
5.1.2.5. Others
5.2. Formulations
5.2.1. Conventional Drug Delivery Formulations
5.2.1.1. Solutions
5.2.1.2. Lyophilized
5.2.1.3. Suspensions
5.2.1.4. Emulsions
5.2.2. Novel Drug Delivery Formulations
5.2.2.1. Colloidal Dispersions
5.2.2.1.1. Niosomes
5.2.2.1.2. Liposomes
5.2.2.1.3. Polymeric Micelles
5.2.2.1.4. Nanoparticles
5.2.2.1.4.1. Solid-Lipid
5.2.2.1.4.2. Nanosuspensions
5.2.2.1.4.3. Nanoemulsions
5.2.2.2. Microparticles
5.2.2.2.1. Microspheres
5.2.2.2.2. Microcapsules
5.2.3. Long-Acting Injection Formulations
CHAPTER 6 GLOBAL INJECTABLE DRUG DELIVERY MARKET – BY
FORMULATION PACKAGING
6.1. Ampules
6.2. Vials
6.3. Cartridges
6.4. Bottles
CHAPTER 7 GLOBAL INJECTABLE DRUG DELIVERY MARKET – BY USAGE
PATTERN
7.1. Curative Curve
7.2. Immunisation
7.3. Others
CHAPTER 8 GLOBAL INJECTABLE DRUG DELIVERY MARKET – BY
ADMINISTRATION SITE
8.1. Skin
8.2. Musculoskeletal System
8.3. Organs
8.4. Central Nervous System
CHAPTER 9 GLOBAL INJECTABLE DRUG DELIVERY MARKET – BY FACILITY
OF USE
9.1. Hospitals and Clinics
9.2. Home Care Settings
9.3. Others
CHAPTER 10 GLOBAL INJECTABLE DRUG DELIVERY MARKET – BY
DISTRIBUTION CHANNEL
10.1. Hospitals
10.2. Retail Pharmacy Stores
CHAPTER 11 GLOBAL INJECTABLE DRUG DELIVERY MARKET – BY
APPLICATION
11.1. Autoimmune Diseases
11.2. Hormonal Diseases
11.3. Orphan Diseases
11.4. Cancer
11.5. Others
CHAPTER 12 GLOBAL INJECTABLE DRUG DELIVERY MARKET - BY
GEOGRAPHY
12.1. Introduction
12.2. North America
12.2.1. U.S.
12.2.2. Canada
12.2.3. Mexico
12.2.4. Costa Rica
12.3. South America
12.3.1. Brazil
12.3.2. Argentina
12.3.3. Chile
12.3.4. Columbia
12.3.5. Others
12.4. Europe
12.4.1. U.K.
12.4.2. Germany
12.4.3. France
12.4.4. Italy
12.4.5. Spain
12.4.6. Russia
12.4.7. Netherlands
12.4.8. Switzerland
12.4.9. Poland
12.4.10. Others
12.5. APAC
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. South Korea
12.5.5. Australia & New Zealand
12.5.6. Malaysia
12.5.7. Singapore
12.5.8. Others
12.6. Middle East & Africa
12.6.1. UAE
12.6.2. Saudi Arabia
12.8.6.3. Iran
12.6.4. Iraq
12.6.5. Qatar
12.6.6. South Africa
12.6.7. Algeria
12.6.8. Morocco
12.6.9. Nigeria
12.6.10. Egypt
12.6.11. Others
CHAPTER 13 GLOBAL INJECTABLE DRUG DELIVERY MARKET - COMPANY
PROFILES
13.1. Antares Pharma Inc.
13.2. Beckton, Dickinson and Company
13.3. Eli Lilly and Company
13.4. Baxter International, Inc.
13.5. Ypsomed Holding AG
13.6. Terumo Medical Corporation
13.7. Schott AG
13.8. Owen Mumford Ltd
13.9. Zogenix, Inc.
13.10. Scandinavian Health Ltd.
13.11. West Pharmaceutical Services, Inc.
13.12. Unilife Corporation
13.13. Elcam Medical
13.14. InjexPharma GmbH
13.15. Nova Nordisk A/S
CHAPTER 14 GLOBAL INJECTABLE DRUG DELIVERY MARKET -
COMPETITIVE LANDSCAPE
14.1. Market Share Analysis
14.2. Strategies adopted by top companies
14.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 15 MARKET INSIGHTS
15.1. Industry Experts Insights
15.2. Analysts Opinions
15.3. Investment Opportunities
CHAPTER 16 APPENDIX
16.1. List of Tables
16.2. List of Figures
